Shares
$
Value
(Cost
and
value
in
$000s)
‡
Surgery
Partners (1)
735,368
40,482
250,253
Total
Services
3,937,830
Total
Miscellaneous
Common
Stocks
4.3% (1)(6)
750,520
Total
Common
Stocks
(Cost
$8,432,195)
16,671,695
CONVERTIBLE
PREFERRED
STOCKS
4.3%
BIOTECHNOLOGY
1.3%
Other
Biotechnology
1.3%
Affinivax,
Series
C,
Acquisition
Date:
1/6/21,
Cost $13,396 (1)(2)
(3)
424,076
13,396
Arbor
Bio,
Series
B,
Acquisition
Date:
10/29/21,
Cost $8,828 (1)
(2)(3)
532,759
8,828
Chroma
Medicine,
Series
A,
Acquisition
Date:
10/12/21,
Cost $11,040 (1)(2)(3)(5)
5,207,526
11,040
Delfi
Diagnostics,
Series
A,
Acquisition
Date:
1/12/21,
Cost $4,465 (1)(2)(3)
2,152,801
4,465
Eikon
Therapeutics,
Series
B,
Acquisition
Date:
12/3/21,
Cost $18,021 (1)(2)(3)
1,018,820
18,021
EndeavorBio,
Series
B,
Acquisition
Date:
1/21/22,
Cost $8,808 (1)
(2)(3)
1,867,734
8,808
FOG
Pharma,
Series
C,
Acquisition
Date:
1/11/21-8/2/21,
Cost $6,251 (1)(2)(3)
431,391
6,251
Generate
Bio,
Series
B,
Acquisition
Date:
9/2/21,
Cost $22,096 (1)
(2)(3)
1,864,632
22,096
Genesis
Therapeutics,
Series
A,
Acquisition
Date:
11/24/20,
Cost $4,236 (1)(2)(3)
829,412
4,236
Insitro,
Series
B,
Acquisition
Date:
5/21/20,
Cost $5,505 (1)(2)(3)
883,580
16,161
Insitro,
Series
C,
Acquisition
Date:
4/7/21,
Cost $10,762 (1)(2)(3)
588,382
10,762
Laronde,
Series
B,
Acquisition
Date:
7/28/21,
Cost $32,757 (1)(2)
(3)
1,169,887
32,757
Nutcracker
Therapeutics,
Series
C,
Acquisition
Date:
8/27/21,
Cost $11,050 (1)(2)(3)
1,027,785
11,050
Prime
Medicine,
Series
B,
Acquisition
Date:
4/19/21,
Cost $7,119 (1)(2)(3)
1,625,121
7,119
Ring
Therapeutics,
Series
B,
Acquisition
Date:
4/12/21,
Cost $9,004 (1)(2)(3)
978,705
9,004
SalioGen
Therapeutics,
Series
B,
Acquisition
Date:
12/10/21,
Cost $11,024 (1)(2)(3)
104,129
11,024
Scribe
Therapeutics,
Series
B,
Acquisition
Date:
3/17/21,
Cost $6,219 (1)(2)(3)
1,027,755
6,219
Sionna
Therapeutics,
Series
B,
Acquisition
Date:
2/2/22,
Cost $5,284 (1)(2)(3)
541,277
5,284